ImmuPharma
Westminster
About ImmuPharma
ImmuPharma focuses in developing pioneering and novel drugs in specialist therapeutic areas where there is a distinct lack of existing treatments, avoiding primary care (diseases treated by GPs) where many treatments exist. This is consistent with the trends in the pharmaceutical industry. Since our foundation, our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value at a relatively low cost, and to work with many leading scientists and doctors. ImmuPharma has exclusive rights to all its intellectual property assets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $22.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: lse:IMM
- Website: immupharma.co.uk
- Phone: +44 20 7206 2650
Industries & Categories
Biotechnology, Developer Tools, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/immupharma-2220339 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.